Japanese businesses wanting to develop techniques for the regeneration of human tissue and commercialize their products are facing a major obstacle.
While pharmaceutical companies envision their products helping countless people and generating enormous profits, the government is slow to react to the rapid advances in technology.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.
We humbly apologize for the inconvenience.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.